Heron Seeks FDA Approval of Postoperative-Nausea Drug

By Matt Grossman

Heron Therapeutics Inc. has submitted a new-drug application seeking U.S. regulatory approval of a drug meant to treat nausea and vomiting that follows surgery.

The Food and Drug Administration filing includes data supporting the bioequivalence of the new drug, HTX-019, with a standard treatment, Heron said. HTX-019 is a proprietary intravenous formulation of that existing treatment, aprepitant.

Giving the drug via IV makes administering it convenient and reliable, Heron said.

More than 65 million diagnostic and surgical procedures that risk causing nausea and vomiting occur in the U.S. each year, Heron said.

Write to Matt Grossman at [e-mail]

(END) Dow Jones Newswires

11-18-21 0807ET